Biojapan / Regenerative Medicine Japan 2018 Partnering Data As of November 2018

BioJapan / Regenerative Medicine Japan 2018 Partnering Data As of November 2018

2019年10月9日(水)〜11日(⾦) Oct. 9WED ー11パシフィコ横浜FRI ――――――――――――――――――October 9–11, 2019 Pacifico Yokohama,Pacifico Japan Yokohama 2019 Japan: the World’s Second Largest Pharmaceutical Market

Representing 8% of the world pharmaceutical market in 2016, Japan’s pharma sector remains one of the largest in the world. While Japan is often said to be overly insular, a recent sharp rise in the number of international forays from larger Japanese pharmaceutical companies—including many significant M&A deals and the establishment of new R&D sites around the world—indicates a bright and increasingly international future for the industry. Furthermore, the nation’s ageing population is creating an ever-larger domestic market for medicinal products and services, and in particular the easing of regulatory restrictions is set to turn Japan into a hotbed for regenerative medicine-related R&D.

1200 Japan

1000 Asia-Pacific (Excl. Japan), 800 Africa, Middle East 600 Europe 400 Central / S. America 200

0 N. America 2012 2013 2014 2015 2016 Source:JPMA Databook

Domestic Japanese Sales Rankings (Distributor Level, FY2017)

Company Sales: USD Company Sales: USD (November 2018 rates) (November 2018 rates) 1 Takeda 6,317,258,929 11 Eli Lilly Japan 2,496,991,071

2 Daiichi Sankyo 5,971,785,714 12 Ono 2,266,526,786

3 Astellas 4,919,303,571 13 Bayer 2,146,785,714

4 Pfizer 4,291,142,857 14 Kyowa Hakko Kirin 2,076,625,000

5 Chugai 4,286,526,786 15 Eizai 1,865,482,143

6 Mitsubishi Tanabe 3,230,785,714 16 Sumitomo Dainippon 1,575,205,357

7 MSD 3,203,116,071 17 AstraZeneca 1,556,473,214

8 Otsuka Holdings 3,036,017,857 18 Nichi-iko 1,490,696,429

9 Novartis 2,702,383,929 19 Santen 1,470,553,571

10 GSK 2,638,955,357 20 Sawai 1,451,696,429

Sales: USD Company (November 2018 rates)

Takeda 15,464,741,071 Astellas 11,711,205,357 Otsuka Holdings 10,674,526,786 Daiichi Sankyo 8,527,892,857 Eisai 4,813,366,071

Mitsubishi Tanabe 3,785,508,929 Dainippon Sumitomo 3,675,339,286 Kyowa Hakko Kirin 3,062,669,643 Shionogi 3,025,803,571 Taisho 2,497,973,214 Ono 2,185,687,500 Santen 1,777,642,857 Hisamitsu 1,302,901,786 Kyorin Holdings 1,030,116,071 Tsumura 1,026,375,000 Kaken 906,062,500 Nippon Shinyaku 881,973,214 Mochida 869,187,500 Kissei 640,232,143 Zaria 579,017,857

Copyright 2018 JTB Communication Design, Inc. 3 Japanese Drug Discovery Alliances Drug discovery alliances between Japanese and non-Japanese organizations are also on the rise. With over half of new medicines now stemming from biotech companies and startups, Japanese pharmaceutical companies understand the potential in developing these new drugs and bringing them to market.

Company Alliance Partner Date Daiichi Sankyo Max Planck Innovation (DEU) 2017 Daiichi Sankyo Bristol-Myers Squibb (USA) 2017 Daiichi Sankyo MD Anderson (USA) 2017 Daiichi Sankyo Glycotope (DEU) 2017 Daiichi Sankyo Puma Biotechnology (USA) 2017 Astellas Universal Cells (USA) 2017 Astellas Ogeda (BEL) 2017 Astellas Affinivax (USA) 2017 Astellas Auration Biotech (USA) 2017 Astellas Ironwood (USA) 2017 Astellas Ganymed Pharmaceuticals (DEU) 2017 Astellas Medicines for Malaria Venture (AUS) 2017 Eisai Arena Pharmacuticals (USA) 2017 Otsuka Jansen (BEL) 2017 Otsuka X-Chem (USA) 2017 Otsuka Mylan (USA) 2017 Otsuka R-Pharm (RUS) 2017 Otsuka Neurovance (USA) 2017 Otsuka Akebia (USA) 2017 Otsuka Teva (ISR) 2017 Taiho Jansen (USA) 2017 Takeda PvP Biologics (USA) 2017 Takeda ARIAD Parmaceuticals (USA) 2017 Takeda Exelixis (USA) 2017 Takeda Maverick Therapeutics (USA) 2017 Takeda Finch Therapeutics (USA) 2017 Takeda Harrington Discovery Institute (USA) 2017 Takeda BioSurfaces (USA) 2017 Takeda TESARO (USA) 2017 Takeda Cardurion Pharmaceuticals (USA) 2017 Takeda Molecular Templates (USA) 2017 Takeda HemoShear Therapeutics (USA) 2017 Takeda Portal Instruments (USA) 2017 Takeda HemoShear Therapeutics (USA) 2017 Takeda NuBiyota (CAN) 2017 Takeda GammaDelta Therapeutics (GBR) 2017 Takeda Medicines for Malaria Venture (CHE) 2017 Takeda Biological E (IND) 2017 Takeda Zydus Cadila (IND) 2017 Ono Merck (USA) 2017 Ono X-Chem (USA) 2017 Ono Numab Therapeutics AG (CHE) 2017 Ono Array Biopharma (USA) 2017 Ono Karyopharm Therapeutics (USA) 2017 Ono Neurimmune Holding (CHE) 2017 Ono Cyclenium Pharma (CAN) 2017

Copyright 2018 JTB Communication Design, Inc. 4 Sources: Company Website Company Alliance Partner Date Ono Schrödinger (USA) 2017 Chugai JW Pharmaceutical (KOR) 2017 Mitsubishi Tanabe NeuroDerm (ISR) 2017 Santen Regenerative Patch Technologies (USA) 2017 KYORIN Merck & Co., Inc. (USA) 2017 BinhDinh Pharmaceutical and KYORIN 2017 Medical Equipment JSC (VNM) TEIJIN PHARMA Merck & Co., Inc. (USA) 2017 TEIJIN PHARMA Merz Pharma GmbH (DEU) 2017 TEIJIN PHARMA Neuronetics,Inc. (USA) 2017 TEIJIN PHARMA SRETT (France) 2018 Astellas Potenza (USA) 2018 Astellas Juventas Therapeutics (USA) 2018 Astellas FibroGen (USA) 2018 Astellas Cytokinetics (USA) 2018 Astellas Quethera (GBR) 2018 Astellas Merck (USA) 2018 Astellas Aquinox Pharamaceuticals (CAN) 2018 Astellas Genetic (USA) 2018 Astellas Mitobridge (USA) 2018 Astellas Vical (USA) 2018 Eisai Bristol-Myers Squibb (USA) 2018 Eisai Eurofarma (BRA) 2018 Eisai CY Biotech (CHN) 2018 Eisai Broad Institute / Colorado St.Univ. (USA) 2018 Otsuka Proteus Digital Health (USA) 2018 Otsuka Visterra (USA) 2018 Taiho Arcus Biosciences (USA) 2018 Taiho Servier（FRA） 2018 Taiho Helsinn (CHE) 2018 Takeda Verily (USA) 2018 Takeda Ambys Medicines (USA) 2018 Drugs for Negelected Diseases initiative Takeda 2018 (CHE) Takeda Valeant (IRL) 2018 Takeda Unipharm (USA) 2018 Takeda Denali Therapeutics (USA) 2018 Ono Merus (NLD) 2018 Chugai Eli Lilly and Company (USA) 2018 Taisho UPSA (FRA) 2018 FUJIFILM Irvine Scientific Sales Company (USA) 2018 FUJIFILM Yestar Healthcare Holdings (CHN) 2018 KYORIN FAES FARMA (ESP) 2018 KYORIN Yissum (IRL) 2018 TEIJIN PHARMA Nox Medical ehf (ISL) 2019 Taiho Cullinana Pearl (USA)

Regulatory Changes Two acts were enacted in Japan in November 2014 that made revolutionary changes to the regulatory system for regenerative medicines: the Pharmaceuticals and Medical Devices Act and the Act on the Safety of Regenerative Medicine.

Pharmaceuticals and Medical Devices Act Under the Pharmaceuticals and Medical Devices Act, a new category for medicinal products called “Regenerative Medical Products” was defined, in addition to the categories of “pharmaceuticals” and “medical devices.” This allows regenerative medical products to be evaluated based on their own unique characteristics. Additionally, a new approval system for regenerative medicine products, diagrammed above, was also introduced as part of this Act. This new system has cut the time required to commercialize regenerative treatment products down to as little as two to three years, making Japan’s approval system the fastest in the world.

Act on the Safety of Regenerative Medicine It is now possible to contract the manufacturing and processing of cells to external enterprises. The culture and processing of cells and tissues for regenerative medicine using human cells could only be conducted by medical institutions under the supervision of the physicians sponsoring the clinical research.

Regenerative Medicine Japan It is with the developments that are set to take place thanks to these new regulatory changes in mind that Regenerative Medicine Japan was first held in October 2016. Organized in collaboration between the Forum for Innovative Regenerative Medicine (FIRM), the Japan Bioindustry Association (JBA), and JTB Communication Design, the new exhibition is co-located with BioJapan, sharing both an exhibition space and partnering system to maximize cross-field collaboration and encourage open innovation.

Japanese pharmaceutical companies are Besides this, many larger companies have becoming more global and strengthening recently been establishing and expanding their pipelines through M&A. To name just R&D sites in countries around the world. one of many, Takeda Pharmaceuticals, Notable examples include Chugai, who are the market leader in Japan, is reported to set to invest almost 500m USD into their have earmarked as much as $20 billion to Singapore research institute over the spend on overseas acquisitions of coming years, and Eisai, who established companies developing cancer, GI, and their first European research site in the CNS drugs in particular. UK in 2009.

Company Takeover Candidate Deal Value (USD) Date

Takeda Shire (UK) 62billion TBD

Mitsubishi Tanabe NeuroDerm (Israel) 1.1 billion Jul. 2017

Sawai Upsher-Smith Laboratories (US) 1 billion Apr. 2017 Pharmaceutical

Hitachi Chemical PCT, LLC, a Caladrius (US) 75 million Mar. 2017

Takara Bio WaferGen (US) 35.9 million 2017

ROHTO Ophthalmos (Brazil) Undisclosed Oct. 2016

Duoc Hau Giang Pharmaceutical Taisho Undisclosed Jul. 2016 (Vietnam)

Nichi-Iko Sagent Pharmaceuticals (US) 736 million Jul. 2016

Eisai Liaoning TianYi (China) 78 million Nov. 2015

ReproCELL Biopta (UK) 8 million Nov. 2015

Astellas Ocata Therapeutics (US) 379 million Nov. 2015

Sosei Group Heptares Therapeutics (UK) 400 million Feb. 2015

Denki Kagaku Kogyo Icon Genetics (Germany) 75 million Aug. 2015

Panasonic Healthcare Bayer Diabetes Care (Germany) 1.1 billion Jun. 2015

Cellular Dynamics International Fujifilm 307 million Mar. 2015 (US)

JSR Corporation KBI Biopharma (US) Undisclosed Feb. 2015

Takeda Neutec (Turkey) *portfolio 121 million Feb. 2015

Sources: NIKKEI Online, Financial Times

1200 1108

983 1000 886 879 782 800 714 678 665 607 551 600 510 538 479 403 327 400 295

200

0 2011 2012 2013 2014 2015 2016 2017 2018

Exhibitor Partnering Member

Partnering

Companies Participants Countries Meetings Held

1,108 1,848 10,075 2018 34 (113%↗) (110%↗) (117%↗)

2017 983 1,666 33 8,591

Exhibitors

Companies Booths Countries Visitors

879 683 16,309 2018 28 (112%↗) (103%↗) (103%↗) of which 114 RMJ of which 107 RMJ

2017 782 658 26 15,711

Pharma CRO/CMO Chemical/Fiber

1 Daiichi Sankyo 1 Fujifilm Wako Pure Chemical 1 Fujifilm 2 Mitsubishi Tanabe Pharma 2 Sekisui Medical 2 Kanto Kagaku 3 Chugai Pharmaceutical Nikon Cell Innovation 3 Hitachi Kasei 4 Astellas Pharma 3 AGC 4 5 Takeda Pharmaceutical Kaneka 5 Kishi Kasei 6 ROHTO Pharmaceutical 5 Nissan Chemical 6 Meiji Seika Phrma 6 Axcelead Drug Discovery Partners 6 TORAY 8 Teijin Pharma Kyokuto Pharmaceutical Indsutrial 7 Mitsubishi Chemical 8 Otsuka Pharmaceutical 7 Oriental Yeast 8 Asahi Kasei Sumitomo Dainippon EPS 10 9 TOSOH Pharma 10 Medinet 1 Mitsui Chemical Eisai Sumika Chemical 0 JSR 11 Kowa 11 CMIC Novartis 1 NOF IQVIA Services Japan 14 Kyowa Hakko Kirin 2 Teijin Kyowa Hakko Bio Nissui Pharmaceutical 1 Sumitomo Chemical 14 Yokohama Bio Research and Supply 15 Taisho Pharmaceutical 4 Nacalai Tesque Shionogi Kishida Chemical Asahi Kasei Pharma Santen Pharmaceutical 18 Daiichi Sankyo RD Novare Machinery/ Manufacturing Taiho Pharmaceutical University/Research Institute 1 Hitachi ASKA Pharmaceutical 22 2 PHC Japan Agency for Medical Research Kyorin Pharmaceutical 1 3 Yokogawa Electric and Development (AMED) Otsuka Pharmaceutical Factory 4 Panasonic 2 The University of Tokyo JCR Pharma 5 Nikon National Institute of Advanced 3 24 Seikagaku 6 Ricoh Industrial Science and Technology Torii Pharmaceutical 7 Toppan Printing 4 Keio University Nobel Pharma 8 Shimadzu 5 Yokohama National University Kaken Pharmaceutical 9 Olympus 6 Waseda University Kissei Pharmaceutical 10 Ushio 7 Toyo University 25 Sanwa Kagaku Kenkyusho 11 Hitach High-Technologies 8 RIKEN Zeria Pharmaceutical 9 Tokyo Institute of Technology 12 SCREEN Holdings Pfizer Teikyo University 13 Canon Osaka University 10 National Center for Global Health 14 Dai Nippon Printing and Medicine 15 Hitachi Appliances Tohoku University Biotech/Drug Discovery Tokyo Medical and Dental University Central Institute of Experimental 1 Cellseed 13 Animals 2 Reprocell Kyoto University Life Science Institute Okayama University 3 Healios Yokohama City University Scohia Pharma 19 Nagoya University Chitose Laboratory Kyushu University 6 20 Kohjin Bio Academia Sinica (Taiwan) Meiji University Regenerative Medicine iPS Gateway 22 Tokyo Univesity of Science 8 Center Tsukuba University Gene Techno Science Tohkai University Reborna Biosciences 25 Hiroshima University 10 Bonac Tech Manage Integriculture

Copyright 2018 JTB Communication Design, Inc. 10 Foreign Pavilions & Clusters Countries / Regions Australia Australian Embassy Australian Pavilion ・ Australia Australian Trade and Investment Commission ・ Austria Belgium BioWin ・ Belgium ★ Embassy of Belgium ・ Canada ★ flanders.bio ・ China Flanders Investment & Trade Walloon Export-Investment Agency (AWEX) ・ Czech Belgium Pavilion ・ Denmark Canada Embassy of Canada to Japan ・ Estonia BIOTECanada ・ Finland Czech CzechInvest Republic ・ France Denmark / ・ Germany ★ Embassy of Sweden, Commercial & Investment Office Sweden ・ Hungary Business Sweden ・ India Invest in Skåne ・ Indonesia Denmark Embassy Medicon Valley Alliance ・ Ireland Copenhagen Capacity ・ Isreal ・ Italy Europe EU-Japan Centre for Industrial Cooperation ・ Japan Japan External Trade Organization (CEE Area) ・ Kazakhstan Finland Embassy of Finland Trade Section ・ Korea Turku Science Park ・ Lithuania France Lyon Biopole Eurobiomed ・ Nepal Germany GTAI ・ Netherland ★ Bavarian Pavilion ・ Poland Berlin Partner for Business and Technology ・ Portugal German Pavilion ・ Singapore BioM ・ Spain Hungary Embassy of Hungary ・ Sweden ★ Italy Embassy of Italy (Trade Promotion Section) Italian Pavilion ・ Switzerland Regione Toscana ・ Taiwan ★ Lithuania Enterprise Lithuania ・ Thailand ★ Lithuania Pavilion ・ UK Netherlands Embassy of the Kingdom of the Netherlands ・ USA Holland Bio Netherland Pavilion *Countries in PINK exhibited Spain ASEBIO 7 consecutive years Embassy of Spain Biocat, BioRegion of Catalonia ICEX Spain Trade and Investment The Americans; 4% Asia / Oceania; 9% Spanish Pavilion Biotechnology and Pharmaceutical Industries Taiwan Promotion Office (BPIPO) Thailand Center of Excellence for Life Sciences Thailand (TCELS) UK MedCity Northern Health Science Alliance UK Pavilion Europe; 20% BioPartner USA Biocom CONNECT Japan; 67%

Partnering Objectives:

Seeking research/development partnerships 1628

Out-licensing products/tech 1340

Selling products/services 1305

In-licensing products/tech 425

Research/development Partnerships 375

Purchasing products/services 152

Other 215

0 500 1000 1500 2000

Professor / Teacher; 2%

Basic research; 2% Machinery / Manufacturing / QC; 1%

Medical doctor / Pharmacist / Intellectual property; 3% Lab technician; 1%

Consultant / Coordinator; 7% Business development / Licensing; 25%

Sales; 7%

Others; 8% Occupation

Planning / Research / PR / R&D; 22% Marketing; 10%

Management; 12%

Incubation facility management; 1.0% Construction / Engineering; 1.0%

Medical institute; 0.7% Logistics / Distribution; 0.2% Food / Beverages; 0.7%

Agriculture and forestry / Fisheries / Livestock; IT / Comms / Bioinformatics ; 1.1% 0.2%

Medical treatment / Diagnosis; 2.4% Law / Patent; 0.3%

Finance / Securities / Investment/ VC / Cosmetics / Toiletries; 0.2% Consulting; 2.0%

Trading / Agent; 2.2% Pharma, 19.4% Chemical / Fibers︔1.1%

Independent administrative agency; 1.6%

Bio-related associations; 2.6%

Machinery / Manufacturing; 3.5% Industry Other, 9.1%

Biotech, 18.6%

Government office / Local gov., 5.8%

CRO / CMO, 12.5% University / Research institute, 13.0%

# of opportunities

466 Small molecules 218 493

429 Medium molecules 209 458

447 Antibodies 203 454

446 Proteins 197 Pharmaceuticals 465

347 Anti-infectives 135 356

357 Vaccines 134 356

304 Generics 84 293

332 Biosimilars 95 324

376 Drug delivery 174 407

381 Cell therapy 176 404

348 Gene therapy 171 373

327 Drug repositioning 128 355

320 Nanomaterials 144 344

347 Diagnostic drugs 111 361

0 100 200 300 400 500 600

Out In Research/development Partnerships

# of opportunities

399 Infectious / Parasitic diseases 107 384 491 Neoplasms / Cancer / Oncology 159 478 391 Diabetes 103 371 Target Illness Target 379 Mental / Behavioral Disorders 142 376 429 Diseases of the nervous system / CNS 177 444 382 Diseases of the eye 117 370 406 Cardiovascular 124 404 375 Respiratory 140 383 404 Digestive System 146 411 397 Skin / Subcutaneous tissue 131 400 389 Musculoskeletal / Connective tissue 135 409 360 Genitourinary system 127 356 Blood / Blood-forming organs / Immune 388 166 disorders 408 Congenital malformations / Chromosomal 324 93 abnormalities 318 334 Diseases of the ear 105 329 372 Endocrine / Nutritional / Metabolic 116 359 434 Unmet medical needs 182 456

0 100 200 300 400 500 600

Out IN Research/development Partnerships

Partnering Objectives

# of opportunities

724 Research 160 559 276 Preclinical 139 289 85 Phase 1 73 95 98 Phase 2 72 108 52 Phase 3 35 58 66 Market 35 R&D Phase Phase of R&D Product 49

0 200 400 600 800

OUT IN Research/development Partnerships

Pharma 1170 Biotech 1174 University / Research institute 768 CRO / CMO 680 Medical treatment / Diagnosis 570 Bio-related associations 483 Medical institute 464 Government office / Local gov. 392 Independent administrative agency 391 Cosmetics / Toiletries 340 Food / Beverages 336 Chemical / Fibers 325 Finance / Securities / Investment/… 273 IT / Comms / Bioinformatics 229 Agriculture and forestry / Fisheries /… 228 Trading / Agent 207 Other 197 Foreign diplomatic offices /… 185 Environment / Energy 173 Machinery / Manufacturing 162 Incubation facility management 130 Press / Media 123 Logistics / Distribution 74 Law / Patent 71 Construction / Engineering 58 HR services 55

0 200 400 600 800 1000 1200

Who did you have meeting with︖ （Exhibitor or Visitor）

Vis VS. Vis 15.0%

Ex VS. Ex 43.4%

Ex VS. Vis 41.7%

Who did you have meeting with︖ （Domestic or International）

Int’l VS. Int’l 13.3%

Dome VS. Dome Dome VS. Int’l 50.9% 35.8%

Academia VS. Academia 0.1%

Company VS. Academia…

Company VS. Company 82.0%

Japanese companies had meeting with…

Int’l Visitor 15.3% Japanese Exhibitor Int’l 36.9% Exhibitor 19.0%

Japanese Visitor 28.8%

Partnering Objectives:

Business collaboration for joint research/ 255 development

Selling/suggesting product/service 252

Out-licensing product/technology 175

In-licensing product/technology 143

Financing for research /development 74

Purchasing/considering product/service 59

Others 20

0 50 100 150 200 250 300

Machinery / Manufacturing / Quality control; 0.7% Basic research; 0.7% Medical doctor / pharmacist / Intellectual property; 1.3% Laboratory technician; 0.3%

Others; 4.3%

Consultant / Coordinator; 7.3% Business development / Licensing; 27.7%

Management; 10.3%

Occupation

Sales; 12.7%

R&D; 21.3% Planning / Research / PR / Marketing; 13.3%

Copyright 2018 JTB Communication Design, Inc. 20 Press / Media; 1.0% Medical institute; 0.7% Law / Patent; 1.0% Foreign diplomatic offices / Institutions; 0.7% Logistics / Distribution; 1.0% Cosmetics / Toiletries; 0.3% IT / Communications / Bioinformatics; 1.3% Independent administrative Food / Beverages; 1.6% agency; 0.3% Construction / Engineering; 2.6%

University / Research institute; 2.6% Pharma; 22.5% Bio-related associations; 2.9% Others; 3.3%

Medical treatment / Diagnosis; 3.3%

Chemical / Fibers; 3.3% Industry

Finance / Securities / Investment institutions / Venture capitals / Consulting; 3.9% CRO / CMO ; 17.6%

Trading / Agent; 4.2% Government office / Local government; 5.2% Biotech; 13.7%

Machinery / Manufacturing; 6.9%

Sought to Discuss:

Cell production/culture Tech and Products # of opportunities

192 39 ES cells 174 214 49 iPS cells 197 214 44 pluripotent stem cells 192 181 40 cancer stem cells 176 209 44 somatic stem cells 196 226 48 mesenchymal cells 207 176 37 hematopoietic stem cells 168 190 41 cell preservation/cell banks 176 199 46 differentiation induction 189 204 39 cell proliferation/differentiation factors 190 154 34 chemokine 153 175 35 angiogenesis 169 184 40 cell sheet 184 185 42 3D culture technology 181 179 41 artificial organs/tissues 174 200 38 cell transplantation/transfer 190 152 34 bone marrow 149 162 36 cord blood 148 159 32 artificial skin 155 174 39 chondrocyte culture 162 152 33 antibody generation 152 142 30 gene cloning 141 140 29 synthesis services 139 170 33 various cell strains 159 0 50 100 150 200 250

Out In Business collaboration for joint research/ development

Copyright 2018 JTB Communication Design, Inc. 22 Drug Discovery # of opportunities 203 Cell for use in drug discovery research 40 192 176 disease-specific iPS cell 46 169 167 liposome/polymer micelle/nanogel, etc. 45 168 169 DDS 46 172 175 gene therapeutics 51 171 160 cancer therapy vaccine 38 153 undifferentiated cell culture/compound 169 39 differentiation induction 162 162 candidate substance screening 41 162 171 iPS cell bank 35 156 186 Tissue Engineering 42 183

0 50 100 150 200 Out In Business collaboration for joint research/ development

Equipment / Reagents /Others # of opportunities 172 Culture medium 31 151 169 Reagents 34 161 137 Serum 30 139 152 Cell processing facility 30 148 168 Cell culture equipment 33 160 172 Cell culture base material 34 168 Cell counting devices / Cell observation 149 28 equipment 139 161 Cell transport/preservation 31 154

0 50 100 150 200 Out In Business collaboration for joint research/ development

October 9-11 (Wed-Fri), 2019 Pacifico Yokohama, Japan

A Partnering Event and Exhibition for the Bio Industry Bringing together key players from around the world working in a diverse range of Biotechnology-related fields.

Copyright 2018 JTB Communication Design, Inc. 24 *layout subject to change A Partnering Event and Exhibition for Regenerative Medicine A global hub for Regenerative Medicine, located in Japan, where recent legislative changes have paved the way for truly groundbreaking developments in the field.

The Forum for Innovative Regenerative Medicine

Cutting-edge Regenerative Medicine Evening Events from Japan and Abroad • 10/9（Wed） Key players from Japan and abroad will Welcome Reception deliver a number of seminars focusing • 10/10（Thu） on groundbreaking changes and the Partnering Parties latest research in the field.

Company Presentations from FIRM Seminars Member Organizations FIRM Member Organizations exhibiting Featuring over 300 seminars at Regenerative Medicine Japan have and presentations on a the chance to deliver a ten-minute diverse range of cutting- presentation on a special stage inside edge topics the Exhibition Hall at no extra cost.

Online Partnering system opens early July

Partnering Registration JPY 80,000 (incl. tax) per person

Includes: • Access to the online Partnering system (completely shared between the two exhibitions) • Access to the exhibition hall, the Annex hall (seminar venue), and the Partnering area • Access to two exclusive evening events

Partnering & Presentation JPY 188,000 (incl. tax) per person

Includes: • One registration for the Partnering system, as detailed above • One 15-minute presentation, delivered at an open stage in the exhibition hall (simultaneous interpretation services available for an additional fee)

Includes: • 4m² Package booth • One registration for the Partnering system

Academic Exhibiting Package Booth (for Universities/Tech Transfer only) JPY 132,000 (incl. tax) per booth

Includes: • 4m² Package booth • 30-minute Presentation hall (simultaneous • interpretation services available for an additional fee) • One registration for the Partnering system

For information on exhibition booth pricing plans, please visit our homepage.

BioJapan / Regenerative Medicine Japan Secretariat Office c/o JTB Communication Design, Inc.

Celestine Shiba Mitsui Building 3-23-1 Shiba, Minato-ku, Tokyo 105-0014 Japan

Tel: +81-3-5657-0758 Fax: +81-3-5657-0645

E-mail: [email protected] Web: www.ics-expo.jp/biojapan/en

E-mail: [email protected] Web: www.ics-expo.jp/saisei/en